Ciclopirox

Ciclopirox

• CAS Number: 29342-05-0
• UNSPSC Description: Ciclopirox (HOE296b) is a synthetic and orally active antifungal agent that can be used for superficial mycoses reseaech. Ciclopirox olamine has a very broad spectrum of activity and inhibits dermatophytes, yeasts, molds, and many Gram-positive and Gram-negative species pathogenic. Ciclopirox also has anticancer and anti-inflammatory effect[1][2][3].
• Target Antigen: Autophagy; Bacterial; Ferroptosis; Fungal
• Type: Reference compound
• Related Pathways: Anti-infection;Apoptosis;Autophagy
• Applications: COVID-19-immunoregulation
• Field of Research: Cancer; Infection; Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/Ciclopirox.html
• Purity: 99.84
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: CC(C=C(C1CCCCC1)N2O)=CC2=O
• Molecular Weight: 207.273
• References & Citations: [1]Niewerth, M., et al., Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob Agents Chemother, 2003. 47(6): p. 1805-17.|[2]Leem, S.H., et al., The possible mechanism of action of ciclopirox olamine in the yeast Saccharomyces cerevisiae. Mol Cells, 2003. 15(1): p. 55-61.|[3]Ratnavel, R.C., R.A. Squire, and G.C. Boorman, Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis. J Dermatolog Treat, 2007. 18(2): p. 88-96.|[4]Clement PM, et al. The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro. Int J Cancer. 2002 Aug 1;100(4):491-8. |[5]Lu J, et al. Ciclopirox targets cellular bioenergetics and activates ER stress to induce apoptosis in non-small cell lung cancer cells. Cell Commun Signal. 2022 Mar 24;20(1):37.|[6]Zhou H, et al. The antitumor activity of the fungicide ciclopirox. Int J Cancer. 2010 Nov 15;127(10):2467-77.Clin Transl Med. 2022 Aug;12(8):e999.|Eur J Pharmacol. 2022 Jul 19;175156.|Front Pharmacol. 2021 May 10;12:670224.|Mol Cell Biochem. 2024 May 24.|Mol Neurobiol. 2024 Oct 10.|Pharmacol Res. 7 January 2022, 106046.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: Launched